---
title: Immunic
date: 2016-09-30T11:25:58Z
modified: 2026-08-11T10:34:25Z
permalink: "https://www.htgf.de/en/portfolio/htgffamily/immunic-2/"
type: portfolio
status: publish
excerpt: ""
wpid: 41609
language:
  - English
post_translations:
  - pll_57ee4bb2d3d65
branchen22:
  - Immunology
sectors:
  - Pharmaceuticals
focus_areas:
  - Immunology
timestamp: 2026-08-11T10:34:25Z
tags:
  - English
  - pll_57ee4bb2d3d65
  - Immunology
  - Pharmaceuticals
---

## Beschreibungstext

Immunic Therapeutics is a clinical-stage biotech company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. Immunic, Inc. is headquartered in New York. Its subsidiary, Immunic AG, is based in Graefelfing near Munich, Germany, where the company’s research and development activities are conducted. Additional subsidiaries are located in Halle/Saale, Germany, and Melbourne, Australia.

Immunic is developing three small molecule products: lead development program, IMU-838, is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function. IMU-838 is in phase 2 clinical development for COVID-19, relapsing-remitting multiple sclerosis, ulcerative colitis and, in collaboration with the Mayo Clinic, primary sclerosing cholangitis.

## Unternehmenswebsite

www.imux.com

## Adresse

Lochhamer Schlag 21
82166 Graefelfing
Germany

## Kontakt

Array

Array